Phoenix Wealth Advisors Grows Holdings in Eli Lilly and Company (NYSE:LLY)

Phoenix Wealth Advisors grew its stake in Eli Lilly and Company (NYSE:LLY) by 7.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 436 shares of the company’s stock after buying an additional 30 shares during the period. Phoenix Wealth Advisors’ holdings in Eli Lilly and Company were worth $258,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Retirement Group LLC lifted its holdings in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the last quarter. Cornerstone Planning Group LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $33,000. Finally, Legacy Financial Group LLC bought a new stake in Eli Lilly and Company during the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $4.03 during trading on Wednesday, reaching $746.74. 2,569,799 shares of the company traded hands, compared to its average volume of 2,215,511. The firm has a 50 day simple moving average of $763.51 and a 200-day simple moving average of $657.01. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $709.52 billion, a PE ratio of 128.75, a P/E/G ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the prior year, the business earned $2.09 EPS. The business’s quarterly revenue was up 28.1% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.